SOCS1-derived peptide

SOCS1-derived peptide (also known as MiS1) is a cell-permeable synthetic peptide that mimics the kinase inhibitory region (KIR) of the endogenous suppressor of cytokine signaling 1 (SOCS1) protein. It acts as a negative regulator of the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway. By binding to the activation loops of Janus kinases (specifically JAK2 and TYK2) and other signaling adaptors like MAL (MyD88-adaptor-like), the peptide suppresses downstream STAT1 and STAT3 phosphorylation and activation. This inhibits the transcription of pro-inflammatory cytokines, chemokines, and angiogenic factors (such as VEGF). Developed by the Vall d'Hebron Research Institute (VHIR), the Hospital Universitario Fundación Jiménez Díaz (IIS-FJD), and the Autonomous University of Madrid (UAM), the peptide has demonstrated therapeutic potential in preclinical models of diabetic retinopathy, diabetic nephropathy, metabolic dysfunction-associated steatotic liver disease (MASLD), and abdominal aortic aneurysm.

Other names

S1 peptideS-1 peptideS 1 peptideSOCS1 kinase inhibitory region peptideSOCS-1 kinase inhibitory region peptideSOCS 1 kinase inhibitory region peptideSOCS1 mimetic peptideSOCS-1 mimetic peptideSOCS 1 mimetic peptideSOCS1-KIR peptideSOCS-1-KIR peptideSOCS 1-KIR peptide